Discussing Post Hoc Analyses from the REACH2 Trial : Episode 4

Post Hoc Analysis Review: REACH2 and Early vs. Late Treatment with Ruxolitinib

April 7, 2023

By Nelson J. Chao, MD, MBA
Michael Grunwald, MD

Video

Panelists engage with a post hoc analysis of the REACH2 trial comparing early versus late treatment with ruxolitinib in patients with steroid-refractory acute Graft-Versus-Host Disease.

EP: 1.Understanding Acute Graft-Versus-Host Disease

EP: 2.Standard Treatments for Patients with Steroid-Refractory Acute Graft-Versus-Host Disease

EP: 3.REACH 2 Post Hoc Analysis Review: and The Impact of Cytopenias on Patient Outcomes

Now Viewing

EP: 4.Post Hoc Analysis Review: REACH2 and Early vs. Late Treatment with Ruxolitinib

EP: 5.Key Takeaways from Two Post Hoc Analyses of the REACH2 Trial

EP: 6.Recap: Post Hoc Analysis Highlights Impact of Cytopenias on Response Rates in Acute GVHD

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!